CENTRUM
ONCOLOGIE
ARTIKELS
ABSTRACT 2
ABSTRACT 1
Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: a case-control study.
The prognostic value of patient-reported health-related quality of life and geriatric assessment in predicting early death in 6769 older (≥ 70 years) patients with different cancer tumors. Quinten C, Kenis C, Decoster L, Debruyne P, et al. Journal of Geriatric Oncology, 2020, DOI: 10.1016/j. jgo.2020.03.017
Tack L, Ketelaars L, Martens E, Stellamans K, Van Eygen K, Werbrouck P, Vergauwe P, Debruyne P, et al. Journal of Geriatric Oncology, 2020, 11(2), 320-326 Zie Inwendige ziekten/gastro-enterologie pagina 25.
OBJECTIVE
ABSTRACT 3
We aimed to determine the prognostic value of baseline Health-Related Quality Of Life (HRQOL) and geriatric assessment (GA) to predict three-month mortality in older patients with cancer undergoing treatment.
PSMA expression on neovasculature of solid tumors. Van de Wiele C, De Jonge P, Debruyne P, Borms M, Beels L, Maes A, et al. Histology and Histopathology, 2020, 35(9), 919-927
MATERIALS/METHODS Logistic regressions analysed HRQOL, as measured with the EORTC Global Health Status (GHS) scale, and geriatric information prognostic for early mortality controlling for oncology variables. The assessment was established with the odds ratio (OR), 95% confidence interval (CI) and level of significance set at p < 0.05. Discriminative power was evaluated with area under the curve (AUC).
Zie Nucleaire geneeskunde pagina 59.
RESULTS
Haaker L, Tryssesoone L, Renders I, Debruyne P, et al. Urologic oncology, 2020, 38(8), DOI: 10.1016/j. urolonc.2020.04.031
In total, 6769 patients were included in the study, of whom 1259 (18.60%) died at three months. Our model showed higher odds of early death for patients with lower HRQOL (GHS, OR 0.98, 95% CI 0.98–0.99; p < 0.001), a geriatric risk profile (G8 Screening Tool, 1.94, 1.14–3.29; p = 0.014), cognitive decline (Mini Mental State Examination, 1.41, 1.15–1.72; p = 0.001), being at risk for malnutrition (Mini Nutritional Assessment–Short Form, 1.54, 1.21–1.98; p = 0.001), fatigue (Visual Analogue Scale for Fatigue, 1.45, 1.16–1.82; p = 0.012) and comorbidities (Charlson Comorbidity index, 1.23, 1.02–1.49; p = 0.033). Additionally, older age, poor ECOG PS and being male increased the odds of early death, although the magnitude differed depending on tumor site and stage, and treatment (all p < 0.05). Predictive accuracy increased with 3.7% when including HRQOL and GA in the model.
62
ABSTRACT 4 Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
OBJECTIVE Papillary renal cell carcinoma (papRCC) is a rare (10%-15%) subtype of renal cancer. Few prognostic biomarkers have been described in metastatic papRCC (m-papRCC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
MATERIALS/METHODS A multicentric, retrospective analysis of patient records was conducted. BM were detected by computed tomography and/or bone scintigraphy. The International Metastatic RCC Database Consortium (IMDC) score was calculated at start of first agent VEGFR-TKI treatment.
CONCLUSION
RESULTS
The results suggest that, in addition to traditional clinical measures, HRQOL and GA provide additional prognostic information for early death, but the odds differ by patient and tumor characteristics.
Forty-nine patients were included. Best objective response was partial response in 20%, stable disease in 60% and early progressive disease in 20% of patients. Median PFS (mPFS) was 6.0 months and median OS (mOS) 14.0 months after start of first agent VEGFR-TKI. The IMDC score
ABSTRACTBOEK | 2020
